Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy
…, G Lepeu, JL Harousseau, JP Eschard, A Ferrant… - Blood, 2006 - ashpublications.org
Dexamethasone alone increases life expectancy in patients with relapsed multiple
myeloma (MM); however, no large randomized study has compared dexamethasone and …
myeloma (MM); however, no large randomized study has compared dexamethasone and …
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party …
…, N Jacobsen, W Arcese, P Ljungman, A Ferrant… - 1995 - ashpublications.org
The immune reactivity of allogeneic lymphocytes plays a major role in the control of
leukemia after bone marrow transplantation. In patients with recurrent leukemia after marrow …
leukemia after bone marrow transplantation. In patients with recurrent leukemia after marrow …
[HTML][HTML] High-dose daunorubicin in older patients with acute myeloid leukemia
…, HC Schouten, C Graux, A Ferrant… - … England Journal of …, 2009 - Mass Medical Soc
Background A complete remission is essential for prolonging survival in patients with acute
myeloid leukemia (AML). Daunorubicin is a cornerstone of the induction regimen, but the …
myeloid leukemia (AML). Daunorubicin is a cornerstone of the induction regimen, but the …
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in …
…, PC Huijgens, H van der Lelie, M Fey, A Ferrant… - Blood, 2007 - ashpublications.org
The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical
Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of patients (…
Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of patients (…
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study
…, JL Garnier, T Lamy, A Jaccard, A Ferrant… - Blood, 2006 - ashpublications.org
B-cell posttransplantation lymphoproliferative disorder (B-PTLD) is a rare but severe complication
of transplantation, with no consensus on best treatment practice. This prospective trial, …
of transplantation, with no consensus on best treatment practice. This prospective trial, …
[HTML][HTML] Cytarabine dose for acute myeloid leukemia
…, HC Schouten, C Graux, A Ferrant… - … England Journal of …, 2011 - Mass Medical Soc
Background Cytarabine (ara-C) is an important drug in the treatment of acute myeloid leukemia
(AML). High-dose cytarabine (2000 to 3000 mg per square meter of body-surface area) …
(AML). High-dose cytarabine (2000 to 3000 mg per square meter of body-surface area) …
[HTML][HTML] Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia
…, H Schouten, G de Greef, A Ferrant… - … England Journal of …, 2003 - Mass Medical Soc
Background Sensitization of leukemic cells with hematopoietic growth factors may enhance
the cytotoxicity of chemotherapy in acute myeloid leukemia (AML). Methods In a multicenter …
the cytotoxicity of chemotherapy in acute myeloid leukemia (AML). Methods In a multicenter …
Bacteraemia in febrile neutropenic cancer patients
…, A Georgala, F Muanza, M Aoun, A Ferrant… - International journal of …, 2007 - Elsevier
A total of 2142 patients with febrile neutropenia resulting from cancer chemotherapy were
registered in two observational studies and followed prospectively in different institutions. …
registered in two observational studies and followed prospectively in different institutions. …
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled …
…, J Maertens, M Schmitt, H Einsele, A Ferrant… - The Lancet infectious …, 2011 - thelancet.com
Background Available drugs against cytomegalovirus have adverse effects that compromise
their prophylactic use in recipients of allogeneic stem-cell transplants. We assessed the …
their prophylactic use in recipients of allogeneic stem-cell transplants. We assessed the …
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
…, MT Daniel, S Cheze, B Mahé, A Ferrant… - Blood, The Journal …, 2008 - ashpublications.org
We analyzed prognostic factors of response, response duration, and possible impact on
survival of epoetin α, epoetin β, or darbepoetin α (DAR) with or without granulocyte colony-…
survival of epoetin α, epoetin β, or darbepoetin α (DAR) with or without granulocyte colony-…